Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Benjamin Chastek, Laura K. Becker, Chieh-I Chen, Puneet Mahajan & Jeffrey R. Curtis. (2017) Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Journal of Medical Economics 20:5, pages 464-473.
Read now
Read now
Machaon MK Bonafede, Jeffrey R Curtis, Donna McMorrow, Puneet Mahajan & Chieh-I Chen. (2016) Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. ClinicoEconomics and Outcomes Research 8, pages 707-715.
Read now
Read now
J. Harnett, D. Wiederkehr, R. Gerber, D. Gruben, A. Koenig & J. Bourret. (2016) Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. Journal of Medical Economics 19:2, pages 101-112.
Read now
Read now
Ning Wu, Sharvari Bhurke, Neel Shah & David J Harrison. (2015) Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. ClinicoEconomics and Outcomes Research 7, pages 257-266.
Read now
Read now
Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah & David J. Harrison. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics 18:5, pages 376-389.
Read now
Read now
Joaquín Borrás-Blasco & Andres Navarro Ruiz. (2015) Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 71-79.
Read now
Read now
Articles from other publishers (14)
Knut Liepe. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging
265
277
.
Knut Liepe. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging
253
264
.
Mahdi GharaibehMachaon BonafedeDonna McMorrowErvant J. Maksabedian HernandezBradley S. Stolshek. (2020) Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data. Journal of Managed Care & Specialty Pharmacy 26:8, pages 1039-1049.
Crossref
Crossref
Jose U. Scher, Renuka R. Nayak, Carles Ubeda, Peter J. Turnbaugh & Steven B. Abramson. (2020) Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nature Reviews Rheumatology 16:5, pages 282-292.
Crossref
Crossref
Natalie Boytsov, Xiang Zhang, Kristin A. Evans & Barbara H. Johnson. (2019) Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis. PharmacoEconomics - Open 4:1, pages 105-117.
Crossref
Crossref
Ryan A. Popp, Karen Rascati, Matthew Davis & Ujas Patel. (2018) Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:2, pages 172-180.
Crossref
Crossref
Michael Grabner, Natalie N. Boytsov, Qing Huang, Xiang Zhang, Tingjian Yan & Jeffrey R. Curtis. (2017) Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Research & Therapy 19:1.
Crossref
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang & Debra F. Eisenberg. (2016) Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes 3:4, pages 369-381.
Crossref
Crossref
Gundula Krack, Henning Zeidler & Jan Zeidler. (2016) Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods. Drugs - Real World Outcomes 3:3, pages 265-278.
Crossref
Crossref
Fredrik Nyberg, Laura Horne, Robert Morlock, Javier Nuevo, Chris Storgard, Lalitha Aiyer, Dionne M. Hines, Xavier Ansolabehere & Pierre Chevalier. (2016) Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis. Advances in Therapy 33:7, pages 1180-1198.
Crossref
Crossref
Marie Hudson, Koray Tascilar & Samy Suissa. (2016) Comparative effectiveness research with administrative health data in rheumatoid arthritis. Nature Reviews Rheumatology 12:6, pages 358-366.
Crossref
Crossref
James Harnett, Jeffrey R. Curtis, Robert Gerber, David Gruben & Andrew Koenig. (2016) Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases. Clinical Therapeutics 38:6, pages 1451-1463.
Crossref
Crossref
Robert Morlock, Pierre Chevalier, Laura Horne, Javier Nuevo, Chris Storgard, Lalitha Aiyer, Dionne M. Hines, Xavier Ansolabehere & Fredrik Nyberg. (2016) Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. Rheumatology and Therapy 3:1, pages 53-75.
Crossref
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang, Debra F. Eisenberg & David J. Harrison. (2015) Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study. Journal of Health Economics and Outcomes Research 3:2, pages 122-131.
Crossref
Crossref